Annual SG&A
$4.79 M
+$38.20 K+0.80%
30 April 2024
Summary:
PharmaCyte Biotech annual selling, general & administrative expenses is currently $4.79 million, with the most recent change of +$38.20 thousand (+0.80%) on 30 April 2024. During the last 3 years, it has risen by +$3.51 million (+274.94%). PMCB annual SG&A is now -38.22% below its all-time high of $7.75 million, reached on 30 April 2006.PMCB Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$783.40 K
-$56.20 K-6.69%
31 July 2024
Summary:
PharmaCyte Biotech quarterly selling, general & administrative expenses is currently $783.40 thousand, with the most recent change of -$56.20 thousand (-6.69%) on 31 July 2024. Over the past year, it has dropped by -$314.90 thousand (-28.67%). PMCB quarterly SG&A is now -86.29% below its all-time high of $5.71 million, reached on 30 April 2006.PMCB Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$441.15 M
+$27.26 M+5.82%
31 July 2024
Summary:
PharmaCyte Biotech TTM selling, general & administrative expenses is currently -$441.15 million, with the most recent change of +$27.26 million (+5.82%) on 31 July 2024. Over the past year, it has dropped by -$445.80 million (-9592.87%). PMCB TTM SG&A is now -68476.50% below its all-time high of $8.90 million, reached on 31 October 2006.PMCB TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.8% | -28.7% | -9592.9% |
| 3 y3 years | +274.9% | +29.6% | -10000.0% |
| 5 y5 years | +129.7% | +29.9% | -10000.0% |
PMCB Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +274.9% | -55.0% | +81.8% | -2.2% | +5.9% |
| 5 y | 5 years | at high | +274.9% | -55.0% | +218.8% | -9.7% | +5.9% |
| alltime | all time | -38.2% | >+9999.0% | -86.3% | +1208.1% | <-9999.0% | +5.9% |
PharmaCyte Biotech Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | $783.40 K(-6.7%) | $3.84 M(-19.8%) |
| Apr 2024 | $4.79 M(+0.8%) | $839.60 K(-25.1%) | $4.79 M(+6.1%) |
| Jan 2024 | - | $1.12 M(+2.1%) | $4.51 M(-2.9%) |
| Oct 2023 | - | $1.10 M(-36.5%) | $4.65 M(-12.1%) |
| July 2023 | - | $1.73 M(+207.9%) | $5.29 M(+11.3%) |
| Apr 2023 | $4.75 M(+120.4%) | $562.10 K(-55.2%) | $4.75 M(+1.1%) |
| Jan 2023 | - | $1.26 M(-27.8%) | $4.70 M(+21.3%) |
| Oct 2022 | - | $1.74 M(+45.8%) | $3.87 M(+41.5%) |
| July 2022 | - | $1.19 M(+134.1%) | $2.74 M(+27.0%) |
| Apr 2022 | $2.16 M(+68.8%) | $509.90 K(+18.3%) | $2.16 M(+2.7%) |
| Jan 2022 | - | $431.00 K(-28.7%) | $2.10 M(+9.6%) |
| Oct 2021 | - | $604.60 K(-1.0%) | $1.92 M(+23.1%) |
| July 2021 | - | $610.90 K(+34.9%) | $1.56 M(+21.8%) |
| Apr 2021 | $1.28 M(-34.1%) | $453.00 K(+83.6%) | $1.28 M(+6.9%) |
| Jan 2021 | - | $246.70 K(+0.4%) | $1.20 M(-8.4%) |
| Oct 2020 | - | $245.70 K(-26.0%) | $1.30 M(-21.5%) |
| July 2020 | - | $332.10 K(-10.5%) | $1.66 M(-14.3%) |
| Apr 2020 | $1.94 M(-7.0%) | $371.00 K(+4.2%) | $1.94 M(-18.1%) |
| Jan 2020 | - | $356.00 K(-41.0%) | $2.37 M(+4.9%) |
| Oct 2019 | - | $603.00 K(-0.9%) | $2.26 M(+4.3%) |
| July 2019 | - | $608.60 K(-23.8%) | $2.16 M(+3.8%) |
| Apr 2019 | $2.09 M(-24.5%) | $798.30 K(+225.0%) | $2.09 M(+1.4%) |
| Jan 2019 | - | $245.60 K(-51.9%) | $2.06 M(-14.4%) |
| Oct 2018 | - | $511.00 K(-3.7%) | $2.40 M(-8.1%) |
| July 2018 | - | $530.40 K(-31.0%) | $2.61 M(-5.4%) |
| Apr 2018 | $2.76 M(+114.3%) | $769.10 K(+30.1%) | $2.76 M(+19.7%) |
| Jan 2018 | - | $591.10 K(-18.3%) | $2.31 M(+14.2%) |
| Oct 2017 | - | $723.30 K(+6.5%) | $2.02 M(+32.4%) |
| July 2017 | - | $679.30 K(+116.4%) | $1.53 M(+18.5%) |
| Apr 2017 | $1.29 M(-53.9%) | $313.90 K(+3.0%) | $1.29 M(-1.6%) |
| Jan 2017 | - | $304.70 K(+33.1%) | $1.31 M(-25.5%) |
| Oct 2016 | - | $229.00 K(-48.1%) | $1.76 M(-24.4%) |
| July 2016 | - | $441.40 K(+31.6%) | $2.32 M(-16.8%) |
| Apr 2016 | $2.79 M(-15.2%) | $335.40 K(-55.4%) | $2.79 M(+17.0%) |
| Jan 2016 | - | $752.30 K(-5.4%) | $2.39 M(-8.7%) |
| Oct 2015 | - | $795.60 K(-12.7%) | $2.61 M(-9.1%) |
| July 2015 | - | $911.10 K(-1388.7%) | $2.88 M(-12.7%) |
| Apr 2015 | $3.29 M(-34.7%) | -$70.70 K(-107.2%) | $3.29 M(-55.0%) |
| Jan 2015 | - | $978.60 K(-7.4%) | $7.32 M(+5.6%) |
| Oct 2014 | - | $1.06 M(-20.5%) | $6.93 M(+12.1%) |
| July 2014 | - | $1.33 M(-66.3%) | $6.18 M(+22.4%) |
| Apr 2014 | $5.05 M | $3.95 M(+571.5%) | $5.05 M(+278.7%) |
| Jan 2014 | - | $588.30 K(+90.8%) | $1.33 M(+37.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2013 | - | $308.40 K(+55.3%) | $970.20 K(+15.1%) |
| July 2013 | - | $198.60 K(-16.2%) | $842.60 K(-16.4%) |
| Apr 2013 | $1.01 M(+20.7%) | $236.90 K(+4.7%) | $1.01 M(-10.7%) |
| Jan 2013 | - | $226.30 K(+25.2%) | $1.13 M(+20.8%) |
| Oct 2012 | - | $180.80 K(-50.4%) | $934.60 K(-20.2%) |
| July 2012 | - | $364.20 K(+1.7%) | $1.17 M(-20.0%) |
| Apr 2012 | $835.50 K(+73.2%) | $358.00 K(+1032.9%) | $1.46 M(+6.2%) |
| Jan 2012 | - | $31.60 K(-92.4%) | $1.38 M(-3.3%) |
| Oct 2011 | - | $417.50 K(-36.4%) | $1.42 M(+37.1%) |
| July 2011 | - | $656.70 K(+141.5%) | $1.04 M(+115.6%) |
| Apr 2011 | $482.30 K(-70.8%) | $271.90 K(+245.1%) | $482.30 K(+7.6%) |
| Jan 2011 | - | $78.80 K(+144.7%) | $448.10 K(-54.6%) |
| Oct 2010 | - | $32.20 K(-67.6%) | $988.00 K(-21.6%) |
| July 2010 | - | $99.40 K(-58.2%) | $1.26 M(-23.6%) |
| Apr 2010 | $1.65 M(-72.2%) | $237.70 K(-61.6%) | $1.65 M(-67.6%) |
| Jan 2010 | - | $618.70 K(+102.9%) | $5.09 M(-6.7%) |
| Oct 2009 | - | $305.00 K(-37.7%) | $5.45 M(-4.1%) |
| July 2009 | - | $489.40 K(-86.7%) | $5.69 M(-3.5%) |
| Apr 2009 | $5.93 M(+39.2%) | $3.67 M(+274.4%) | $5.89 M(+69.4%) |
| Jan 2009 | - | $981.60 K(+81.6%) | $3.48 M(-4.6%) |
| Oct 2008 | - | $540.60 K(-22.3%) | $3.65 M(-5.1%) |
| July 2008 | - | $696.00 K(-44.8%) | $3.84 M(-9.8%) |
| Apr 2008 | $4.26 M(-4.7%) | $1.26 M(+9.7%) | $4.26 M(-1.0%) |
| Jan 2008 | - | $1.15 M(+55.9%) | $4.30 M(+8.7%) |
| Oct 2007 | - | $737.60 K(-33.6%) | $3.96 M(-1.2%) |
| July 2007 | - | $1.11 M(-14.7%) | $4.00 M(-10.7%) |
| Apr 2007 | $4.47 M(-42.3%) | $1.30 M(+62.0%) | $4.48 M(-49.6%) |
| Jan 2007 | - | $804.00 K(+2.6%) | $8.90 M(-0.0%) |
| Oct 2006 | - | $784.00 K(-50.8%) | $8.90 M(+7.8%) |
| July 2006 | - | $1.59 M(-72.1%) | $8.25 M(+6.4%) |
| Apr 2006 | $7.75 M(+350.1%) | $5.71 M(+609.4%) | $7.75 M(+116.4%) |
| Jan 2006 | - | $805.60 K(+475.0%) | $3.58 M(+26.6%) |
| Oct 2005 | - | $140.10 K(-87.2%) | $2.83 M(+2.3%) |
| July 2005 | - | $1.09 M(-29.3%) | $2.77 M(+39.8%) |
| Apr 2005 | $1.72 M(+429.7%) | $1.54 M(+2819.1%) | $1.98 M(+184.1%) |
| Jan 2005 | - | $52.90 K(-30.9%) | $696.50 K(+2.5%) |
| Oct 2004 | - | $76.60 K(-74.9%) | $679.50 K(+10.0%) |
| July 2004 | - | $305.30 K(+16.7%) | $617.60 K(+89.9%) |
| Apr 2004 | $325.20 K(+913.1%) | $261.70 K(+629.0%) | $325.20 K(+412.1%) |
| Jan 2004 | - | $35.90 K(+144.2%) | $63.50 K(+130.1%) |
| Oct 2003 | - | $14.70 K(+14.0%) | $27.60 K(+114.0%) |
| July 2003 | - | $12.90 K | $12.90 K |
| Apr 2003 | $32.10 K | - | - |
FAQ
- What is PharmaCyte Biotech annual selling, general & administrative expenses?
- What is the all time high annual SG&A for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual SG&A year-on-year change?
- What is PharmaCyte Biotech quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly SG&A year-on-year change?
- What is PharmaCyte Biotech TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for PharmaCyte Biotech?
- What is PharmaCyte Biotech TTM SG&A year-on-year change?
What is PharmaCyte Biotech annual selling, general & administrative expenses?
The current annual SG&A of PMCB is $4.79 M
What is the all time high annual SG&A for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual selling, general & administrative expenses is $7.75 M
What is PharmaCyte Biotech annual SG&A year-on-year change?
Over the past year, PMCB annual selling, general & administrative expenses has changed by +$38.20 K (+0.80%)
What is PharmaCyte Biotech quarterly selling, general & administrative expenses?
The current quarterly SG&A of PMCB is $783.40 K
What is the all time high quarterly SG&A for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly selling, general & administrative expenses is $5.71 M
What is PharmaCyte Biotech quarterly SG&A year-on-year change?
Over the past year, PMCB quarterly selling, general & administrative expenses has changed by -$314.90 K (-28.67%)
What is PharmaCyte Biotech TTM selling, general & administrative expenses?
The current TTM SG&A of PMCB is -$441.15 M
What is the all time high TTM SG&A for PharmaCyte Biotech?
PharmaCyte Biotech all-time high TTM selling, general & administrative expenses is $8.90 M
What is PharmaCyte Biotech TTM SG&A year-on-year change?
Over the past year, PMCB TTM selling, general & administrative expenses has changed by -$445.80 M (-9592.87%)